| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5541171 | ABBVIE | Orally administrable pharmaceutical composition |
Jul, 2013
(10 years ago) | |
| US5541170 | ABBVIE | Orally administrable pharmaceutical compositions |
Jul, 2013
(10 years ago) | |
| US9089492 | ABBVIE | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
Nov, 2021
(2 years ago) | |
| US6893662 | ABBVIE | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
Nov, 2021
(2 years ago) | |
| US8580302 | ABBVIE | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
Nov, 2021
(2 years ago) | |
Asacol Hd is owned by Abbvie.
Asacol Hd contains Mesalamine.
Asacol Hd has a total of 5 drug patents out of which 5 drug patents have expired.
Expired drug patents of Asacol Hd are:
- US5541171
- US5541170
- US9089492
- US6893662
- US8580302
Asacol Hd was authorised for market use on 29 May, 2008.
Asacol Hd is available in tablet, delayed release;oral dosage forms.
Asacol Hd can be used as treatment of ulcerative colitis.
The generics of Asacol Hd are possible to be released after 15 November, 2021.
Drugs and Companies using MESALAMINE ingredient
Market Authorisation Date: 29 May, 2008
Treatment: Treatment of ulcerative colitis
Dosage: TABLET, DELAYED RELEASE;ORAL
How can I launch a generic of ASACOL HD before it's drug patent expiration?
More Information on Dosage
ASACOL HD family patents
